Effect of berberine on PPAR_α-NO signalling pathway in vascular smooth muscle cell proliferation induced by angiotensin IV

References

• Cheang WS, Tian XY, Wong WT, Huang Y. 2015. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol. 172:5512–5522.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Bowman L, D'Arsigny CL, Archer SL. 2015. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther. 97:88–102.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Cicero AF. 2012. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 12:1113–1124.
   PubMed Web of Science ®Google Scholar
• Dominska K, Piastowska-Ciesielska AW, Pluciennik E, Lachowicz-Ochedalska A, Ochedalski T. 2013. A comparison of the effects of angiotensin IV on androgen-dependent and androgen-independent prostate cancer cell lines. J Renin Angiotensin Aldosterone Syst. 14:74–81.
   PubMed Web of Science ®Google Scholar
• Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, Jones KL, Staels B, Bruemmer D. 2008. The PPARalpha/p16 INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circ Res. 103:1155–1163.
   PubMed Web of Science ®Google Scholar
• Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. 2009. PPARs and the cardiovascular system. Antioxid Redox Signal. 11:1415–1452.
   PubMed Web of Science ®Google Scholar
• Hu ZW, Kerb R, Shi XY, Wei-Lavery T, Hoffman BB. 2002. Angiotensin II increases expression of cyclooxygenase-2: implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther. 303:563–573.
   PubMed Web of Science ®Google Scholar
• Ji YY, Liu JT, Liu N, Wang ZD, Liu CH. 2009. PPARalpha activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway. Biochem Pharmacol. 78:1186–1197.
   PubMed Web of Science ®Google Scholar
• Lei J, Vodovotz Y, Tzeng E, Billiar TR. 2013. Nitric oxide, a protective molecule in the cardiovascular system. Nitric Oxide. 35:175–185.
   PubMed Web of Science ®Google Scholar
• Liang KW, Yin SC, Ting CT, Lin SJ, Hsueh CM, Chen CY, Hsu SL. 2008. Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. Eur J Pharmacol. 590:343–354.
   PubMed Web of Science ®Google Scholar
• Lim GB. 2013. Global burden of cardiovascular disease. Nat Rev Cardiol. doi: 10.1038/nrcardio.2012.194.
   Google Scholar
• Liu J, Xiu J, Cao J, Gao Q, Ma D, Fu L. 2011. Berberine cooperates with adrenal androgen dehydroepiandrosterone sulfate to attenuate PDGF-induced proliferation of vascular smooth muscle cell A7r5 through Skp2 signaling pathway. Mol Cell Biochem. 355:127–134.
   PubMed Web of Science ®Google Scholar
• Liu SJ, Yin CX, Ding MC, Xia SY, Shen QM, Wu JD. 2014. Berberine suppresses in vitro migration of human aortic smooth muscle cells through the inhibitions of MMP-2/9, u-PA, AP-1, and NF-κB. BMB Rep. 47:388–392.
   PubMed Web of Science ®Google Scholar
• Lu J, Zhang J, Block ER, Patel JM. 2005. Angiotensin IV enhances phosphorylation of 4EBP1 by multiple signaling events in lung endothelial cells. Mol Cell Biochem. 275:181–188.
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang L, Peng T, Cheng J, Taneja S, Zhang J, Delafontaine P, Du J. 2006. Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB. Endocrinology. 147:1256–1263.
   PubMed Web of Science ®Google Scholar
• Moran EP, Ma JX. 2015. Therapeutic effects of PPAR α on neuronal death and microvascular impairment. PPAR Res. 2015:595426.
   PubMed Web of Science ®Google Scholar
• Mueller M, Hobiger S, Jungbauer A. 2010. Red clover extract: a source for substances that activate peroxisome proliferator-activated receptor alpha and ameliorate the cytokine secretion profile of lipopolysaccharide-stimulated macrophages. Menopause. 17:379–387.
   PubMed Web of Science ®Google Scholar
• Pawlikowski M, Gruszka A, Mucha S, Melen-Mucha G. 2001. Angiotensins II and IV stimulate the rat adrenocortical cell proliferation acting via different receptors. Endocr Regul. 35:139–142.
   PubMedGoogle Scholar
• Pirillo A, Catapano AL. 2015. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis. 243:449–461.
   PubMed Web of Science ®Google Scholar
• Ptasinska-Wnuk D, Kunert-Radek J, Pawlikowski M. 2003. Angiotensins II and IV stimulate the rat anterior pituitary cell proliferation independently of the AT1 receptor subtype. Neuro Endocrinol Lett. 24:397–400.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Vita J, Sánchez-López E, Esteban V, Rupérez M, Egido J, Ruiz-Ortega M. 2005. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation. 111:2509–2517.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Esteban V, Egido J. 2007. The regulation of the inflammatory response through nuclear factor-kappa B pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc Med. 17:19–25.
   PubMed Web of Science ®Google Scholar
• Sata M, Fukuda D. 2010. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest. 57:12–25.
   PubMedGoogle Scholar
• Shi N, Chen SY. 2015. Smooth muscle cell differentiation: model systems, regulatory mechanisms, and vascular diseases. J Cell Physiol. 231:777–787.
   PubMed Web of Science ®Google Scholar
• Wang M, Wang J, Tan R, Wu Q, Qiu H, Yang J, Jiang Q. 2013. Effect of berberine on PPAR α /NO activation in high glucose- and insulin-induced cardiomyocyte hypertrophy. Evid Based Complement Alternat Med. 2013:285489.
   PubMed Web of Science ®Google Scholar
• Wu M, Wang J, Liu LT. 2010. Advance of studies on anti-atherosclerosis mechanism of berberine. Chin J Integr Med. 16:188–192.
   PubMed Web of Science ®Google Scholar
• Xiao M, Men LN, Xu MG, Wang GB, Lv HT, Liu C. 2014. Berberine protects endothelial progenitor cell from damage of TNF-α via the PI3K/AKT/eNOS signaling pathway. Eur J Pharmacol. 743:11–16.
   PubMed Web of Science ®Google Scholar
• Xu T, Zhu H, Li D, Lang Y, Cao L, Liu Y, Wu W, Chen D. 2015. Luteolin inhibits angiotensin II-stimulated VSMC proliferation and migration through downregulation of Akt phosphorylation. Evid Based Complement Alternat Med. 2015:931782.
   PubMedGoogle Scholar
• Yakubu MA, Nsaif RH, Oyekan AO. 2010. Regulation of cerebrovascular endothelial peroxisome proliferator activator receptor alpha expression and nitric oxide production by clofibrate. Bratisl Lek Listy. 111:258–264.
   PubMed Web of Science ®Google Scholar
• Yang H, Zeng XJ, Wang HX, Zhang LK, Dong XL, Guo S, Du J, Li HH, Tang CS. 2011. Angiotensin IV protects against angiotensin II-induced cardiac injury via AT4 receptor. Peptides. 32:2108–2115.
   PubMed Web of Science ®Google Scholar
• Yousefipour Z, Newaz M. 2014. PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats. Acta Pharmacol Sin. 35:476–482.
   PubMed Web of Science ®Google Scholar